The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing
Abomasal (gastric) ulceration is a morbidity in sheep, and currently, there is a paucity of pharmacokinetic and pharmacodynamic data for gastroprotectant drugs reported for this species. The proton pump inhibitor esomeprazole has been used in small animal and human patients for gastroprotection via...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Veterinary Science |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fvets.2023.1172023/full |
| _version_ | 1797833077863481344 |
|---|---|
| author | Joe S. Smith Joe S. Smith Jessica Gebert Kailee Bennett Lisa Sams Ebner Ryan Flynn Pierre-Yves Mulon Lainey Harvill Olivia Grace Escher Amanda Jo Kreuder Joan Bergman Sherry Cox |
| author_facet | Joe S. Smith Joe S. Smith Jessica Gebert Kailee Bennett Lisa Sams Ebner Ryan Flynn Pierre-Yves Mulon Lainey Harvill Olivia Grace Escher Amanda Jo Kreuder Joan Bergman Sherry Cox |
| author_sort | Joe S. Smith |
| collection | DOAJ |
| description | Abomasal (gastric) ulceration is a morbidity in sheep, and currently, there is a paucity of pharmacokinetic and pharmacodynamic data for gastroprotectant drugs reported for this species. The proton pump inhibitor esomeprazole has been used in small animal and human patients for gastroprotection via increasing the gastric pH. The objective of this study was to report the pharmacokinetic parameters and pharmacodynamic effect of esomeprazole in sheep after single intravenous dosing. Four healthy adult Southdown cross ewes had blood collected over a 24 h time period after single intravenous dosing of esomeprazole at 1.0 mg/kg. Abomasal fluid was sampled over 24 h before and after esomeprazole administration. Plasma samples were analyzed for concentrations of esomeprazole and the esomeprazole metabolite, esomeprazole sulfone by high performance liquid chromatography. Pharmacokinetic and pharmacodynamic data were evaluated with specialized software. Esomeprazole was rapidly eliminated after IV administration. Elimination half-life, area under the curve, initial concentration (C0), and clearance were 0.2 h, 1,197 h*ng/mL, 4,321 ng/mL, and 0.83 mL/h/kg, respectively. For the sulfone metabolite elimination half-life, area under the curve and maximum concentration were 0.16 h, 22.5 h*ng/mL, and 65.0 ng/mL, respectively. Abomasal pH was significantly elevated from 1 to 6 h after administration and remained above 4.0 for at least 8 h after administration. No adverse effects were noted in these sheep. Esomeprazole was rapidly eliminated in sheep, similar to goats. Abomasal pH was increased, but future studies will be necessary to develop a clinical management approach to the use of esomeprazole in sheep. |
| first_indexed | 2024-04-09T14:19:02Z |
| format | Article |
| id | doaj.art-e7aeba1a071a4c239561c934b3347603 |
| institution | Directory Open Access Journal |
| issn | 2297-1769 |
| language | English |
| last_indexed | 2024-04-09T14:19:02Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Veterinary Science |
| spelling | doaj.art-e7aeba1a071a4c239561c934b33476032023-05-05T05:44:54ZengFrontiers Media S.A.Frontiers in Veterinary Science2297-17692023-05-011010.3389/fvets.2023.11720231172023The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosingJoe S. Smith0Joe S. Smith1Jessica Gebert2Kailee Bennett3Lisa Sams Ebner4Ryan Flynn5Pierre-Yves Mulon6Lainey Harvill7Olivia Grace Escher8Amanda Jo Kreuder9Joan Bergman10Sherry Cox11Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United StatesBiomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, United StatesLincoln Memorial University, College of Veterinary Medicine, Harrogate, TN, United StatesLarge Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United StatesLincoln Memorial University, College of Veterinary Medicine, Harrogate, TN, United StatesLarge Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United StatesLarge Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United StatesBiomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United StatesLarge Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United StatesVeterinary Microbiology and Preventative Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, United StatesBiomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United StatesBiomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United StatesAbomasal (gastric) ulceration is a morbidity in sheep, and currently, there is a paucity of pharmacokinetic and pharmacodynamic data for gastroprotectant drugs reported for this species. The proton pump inhibitor esomeprazole has been used in small animal and human patients for gastroprotection via increasing the gastric pH. The objective of this study was to report the pharmacokinetic parameters and pharmacodynamic effect of esomeprazole in sheep after single intravenous dosing. Four healthy adult Southdown cross ewes had blood collected over a 24 h time period after single intravenous dosing of esomeprazole at 1.0 mg/kg. Abomasal fluid was sampled over 24 h before and after esomeprazole administration. Plasma samples were analyzed for concentrations of esomeprazole and the esomeprazole metabolite, esomeprazole sulfone by high performance liquid chromatography. Pharmacokinetic and pharmacodynamic data were evaluated with specialized software. Esomeprazole was rapidly eliminated after IV administration. Elimination half-life, area under the curve, initial concentration (C0), and clearance were 0.2 h, 1,197 h*ng/mL, 4,321 ng/mL, and 0.83 mL/h/kg, respectively. For the sulfone metabolite elimination half-life, area under the curve and maximum concentration were 0.16 h, 22.5 h*ng/mL, and 65.0 ng/mL, respectively. Abomasal pH was significantly elevated from 1 to 6 h after administration and remained above 4.0 for at least 8 h after administration. No adverse effects were noted in these sheep. Esomeprazole was rapidly eliminated in sheep, similar to goats. Abomasal pH was increased, but future studies will be necessary to develop a clinical management approach to the use of esomeprazole in sheep.https://www.frontiersin.org/articles/10.3389/fvets.2023.1172023/fullabomasal ulcerabomasal ulcerationewegastricgastroprotectantproton pump inhibitor (PPI) |
| spellingShingle | Joe S. Smith Joe S. Smith Jessica Gebert Kailee Bennett Lisa Sams Ebner Ryan Flynn Pierre-Yves Mulon Lainey Harvill Olivia Grace Escher Amanda Jo Kreuder Joan Bergman Sherry Cox The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing Frontiers in Veterinary Science abomasal ulcer abomasal ulceration ewe gastric gastroprotectant proton pump inhibitor (PPI) |
| title | The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing |
| title_full | The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing |
| title_fullStr | The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing |
| title_full_unstemmed | The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing |
| title_short | The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing |
| title_sort | pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing |
| topic | abomasal ulcer abomasal ulceration ewe gastric gastroprotectant proton pump inhibitor (PPI) |
| url | https://www.frontiersin.org/articles/10.3389/fvets.2023.1172023/full |
| work_keys_str_mv | AT joessmith thepharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT joessmith thepharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT jessicagebert thepharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT kaileebennett thepharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT lisasamsebner thepharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT ryanflynn thepharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT pierreyvesmulon thepharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT laineyharvill thepharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT oliviagraceescher thepharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT amandajokreuder thepharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT joanbergman thepharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT sherrycox thepharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT joessmith pharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT joessmith pharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT jessicagebert pharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT kaileebennett pharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT lisasamsebner pharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT ryanflynn pharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT pierreyvesmulon pharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT laineyharvill pharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT oliviagraceescher pharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT amandajokreuder pharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT joanbergman pharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing AT sherrycox pharmacokineticsandpharmacodynamicsofesomeprazoleinsheepafterintravenousdosing |